| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,140,000 |
| Market
Cap: |
732.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$26.52 - $75.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
652,175 |
| Total Buy Value |
$0 |
$0 |
$0 |
$15,000,025 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
28,918 |
1,809,345 |
3,899,867 |
3,922,367 |
| Total Sell Value |
$2,009,702 |
$108,295,610 |
$210,114,411 |
$210,161,436 |
| Total People Sold |
2 |
8 |
12 |
13 |
| Total Sell Transactions |
3 |
33 |
52 |
53 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Meyenburg Jason Patrick |
President & CEO |
• • – |
2021-05-14 |
4 |
B |
$9.46 |
$122,929 |
D/D |
13,000 |
13,000 |
2.81 |
-54% |
|
| Piekos Brian |
Chief Financial Officer |
• – – |
2021-05-14 |
4 |
B |
$9.46 |
$72,432 |
D/D |
7,655 |
7,655 |
2.74 |
-54% |
|
| George Jean |
Director |
– • • |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,836,106 |
|
- |
|
| Plain Henry A Jr |
10% Owner |
– – • |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,836,106 |
|
- |
|
| Atlas Venture Associates Xii, Llc |
10% Owner |
– – • |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,254,365 |
|
- |
|
| Rhodes Jason P |
Director |
– • – |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,254,365 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • • |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,826,224 |
|
- |
|
| Lauder Scott |
Chief Technology OfficerOffice |
• – – |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
104,622 |
|
- |
|
| Gordon Carl L |
Director |
– • • |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,826,224 |
|
- |
|
| Tananbaum James B. |
Director |
– • – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
I/I |
2,928,750 |
2,928,750 |
|
- |
|
| Tananbaum James B. |
Director |
– • – |
2021-02-05 |
4 |
A |
$10.00 |
$15,000,000 |
I/I |
1,500,000 |
1,500,000 |
|
- |
|
| Foresite Capital Opportunity Management V, Llc |
Director by Deputization |
– – • |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,928,750 |
2,928,750 |
|
- |
|
| Foresite Capital Opportunity Management V, Llc |
Director by Deputization |
– – • |
2021-02-05 |
4 |
A |
$10.00 |
$15,000,000 |
D/D |
1,500,000 |
1,500,000 |
|
- |
|
| Foresite Capital Opportunity Management V, Llc |
10% Owner |
– – • |
2020-10-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
441,500 |
|
- |
|
| Tananbaum James B. |
President & CEO |
• • • |
2020-08-14 |
4 |
B |
$10.00 |
$4,415,000 |
D/D |
441,500 |
441,500 |
3.23 |
- |
|
115 Records found
|
|
Page 5 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.41 (1.33%) 
